Mersana Therapeutics Inc (MRSN.OQ)
23 May 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
- BRIEF-Mersana Therapeutics Q4 Loss Per Share $0.61
- BRIEF-Mersana Strengthens Board Of Directors Leadership With Appointment Of Willard H. Dere, M.D
- BRIEF-Mersana Therapeutics Increased Size Of Board From 7 To 8 Directors
- BRIEF-Mersana Appoints David Spellman As Chief Financial Officer
- BRIEF-Mersana Announces First Patient Dosed With XMT-1536 In Phase 1 Study In Patients With NaPi2b-Expressing Tumors